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Abstract
Background: Patients aged 65 years and older are not traditionally considered optimal candidates for subthalamic
deep brain stimulation (STN-DBS), mainly for their presumed increased incidence of surgical complications. The aim
of this study was to assess STN-DBS surgery safety in relation to age.
Methods: A total of 107 consecutive patients undergoing bilateral STN-DBS at our institution between 2002 and
2014 were retrospectively stratified according to age in two groups (Young group < 65 years old; Elderly group ≥
65 years old;). Rate of short-term surgical complications (within 90 days) was reviewed and compared between the
two groups.
Results: Pre-operative baseline data were comparable between the two groups. The 90-days post-operative
mortality rate was 0%. Overall incidence of complications related to surgery was 6,54%. In the Elderly group we
observed 3 post-operative intra-cerebral haematomas (7,89%), 1 requiring urgent surgical evacuation. In the Young
group we observed 2 post-operative asymptomatic intra-cerebral haematomas (2,89%) and 2 wound infections
(2,89%), 1 requiring system removal. No others surgical complications were noticed in both groups.
Conclusions: Chronological age ≥ 65 years old should not be considered alone as exclusion criteria to STN-DBS
surgery.
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Background
Deep brain stimulation (DBS) can be considered one of
the greatest revolutions occurred in the field of functional
neurosurgery during the last 20 years [1]. Despite its thera-
peutic applications are expanding day by day, DBS main
indication still remains the treatment of patients affected
by advanced Parkinson’s Disease (PD). Among DBS stand-
ard targets, the subthalamic nucleus is considered the
anatomical site of choice for the treatment of PD (STN-
DBS) [2, 3].
Patients candidates for STN-DBS usually have a mean
age at surgery of 58.6 years, a disease duration > 14 years
and severe levodopa-induced motor complications [2–6].
Many neurosurgeons tend to avoid operating on patients
aged 65 years and older because of their diminished
“surgical tolerance”, which would be responsible for a raise
of surgical complications [7–9].
It is well known, however, that PD incidence increases
with time, and that mean age at diagnosis is 60 years
[10, 11]. By 2030 patients affected by PD are expected to
double [12]. Simultaneously, a quarter of the European
population will be referred to as elderly (≥65 years old)
[13, 14]. Considering these epidemiologic data, an in-
creasing number of elderly patients will require STN-DBS
for the treatment of PD in the next future. Guaranteeing
an adequate evidence-based counselling by estimating the
real surgical risks of this population will be paramount.
Although few prior studies suggested that the rate
of surgical complications increases preferentially for
older patients, scant literature has directly addressed
the relationship between patient age and STN-DBS
surgical adverse events in the PD population [15–17].
In addition, a recent study by DeLong et al. demonstrated
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a similar 90-days DBS surgical complication risk for
elderly patients and younger counterparts, producing
therefore contradictory findings [18].
Purpose of this study is to assess the potential negative
role of age ≥ 65 years old on short-termsurgical compli-
cations in a specific population of patients undergoing
STN-DBS for the treatment of PD.
Methods
We retrospectively analysed surgical complications
within 90 days in a cohort of 107 consecutive patients
who underwent STN-DBS for the treatment of PD at
our institution between 2002 and 2014. Selection criteria
were the following: clinically diagnosed PD with severe
motor fluctuations or dyskinesia not responsive to best
medical therapies, a positive L-Dopa challenge test and a
normal brain magnetic resonance imaging (MRI). Exclu-
sion criteria were atypical parkinsonism, dementia or
psychiatric impairment. For the purpose of this study,
patients were stratified in two different subgroups ac-
cording to age at time of surgery: patients younger
than 65 years (Young group; n = 69) and patients aged
65 years and older (Elderly group; n = 38). The follow-
ing permanent post-operative complications were
reviewed: haemorrhagic and ischemic stroke, seizure,
wound infection, hardware complication, pulmonary
embolism and pneumonia. A Charlson comorbidity
index ≥1 was used to assess the burden of risk factors
in both groups [15].
Descriptive statistics were displayed as mean ± standard
deviation for continuous data. Fisher’s exact test was used
to compare qualitative data, with a P value set at 0.05.
This was a large retrospective study without patient con-
tact, required consent, or financial compensation.
Surgical procedure
A stereotactic frame (Radionics CRW™ Stereotactic
Frame, Integra, USA) was placed under local anaesthesia
in the operating theatre after 24 hours medication with-
drawal. A pre-operative stereotactic CT scan was usually
fused with a cerebral MRI obtained the day before
surgery. Volumetric T2-weighted sequences (slice thick-
ness = 2 mm) and T1-weighted sequences with gadolin-
ium were acquired in order to clearly localize subthalamic
nucleus and avoid danger to vessels along the planned tra-
jectory (Istereotaxy, Brainlab, Kapellenstrat, Germany).
A movement disorder neurologist performed intraop-
erative electrophysiological mapping and acute stimula-
tion test in all cases. Microelectrode recordings were
performed with 0,5 mm step checkpoints. Threshold for
adverse events was routinely investigated.
Implantation of electrodes was always performed bilat-
erally in a single operation. The electrodes were then
connected to a pulse generator (Kinetra o Activa Pc,
Medtronic Inc, Minneapolis, Usa) 4 days later. Stimulation
parameters and dopaminergic therapies were adapted
postoperatively at 1, 6 and 12 months by a movement dis-
order neurologist.
Results
Baseline characteristics among subgroups were found to
be similar in terms of sex, disease duration, UPDRS III,
UPDRS IV, Charlson comorbidity index and Levodopa
equivalent dose (LED) [Table 1]. Mean age in the Elderly
group was 68 ± 2,34 years ( range 65–75 years), compared
to 57 ± 5,54 years of the younger counterpart (range,
42–64 years). The preoperative mean UPDRS III OFF in
the Elderly group and the Young group was found to be
42 ± 12.34 and 44 ± 12,01 respectively (p = 0,7). Mean
preoperative UPDRS IV dyskinesia subscore was slightly
worse in the Young group (4 ± 2,10 versus 3 ± 1,50,
p = 0,3). The preoperative UPDRS III assessed in ON
state, instead, was higher for the Elderly group as
expected, but the difference was not statistically signifi-
cant (7 ± 5,59 versus 10 ± 5,57, p = 0,16). Mean disease
duration of the entire cohort at the time of surgery
was 13 ± 4,39 years (no differences between the two
groups, p = 0,6).
The 90-days post-operative mortality rate was 0 %.
Overall incidence of complications related to surgery
was low (6,54 %) [Table 2]. In the Elderly group we
observed 3 post-operative intra-cerebral haematomas,
1 requiring urgent surgical evacuation (7,89 % - 2
females and 1 male). In the Young group we observed
2 post-operative asymptomatic intra-cerebral haemato-
mas (2,89 % - 2 males) and 2 wound infections, 1 requiring
system removal (2,89 %,- 2 males). Transient post-operative
confusion (<24 h) was noticed in 5 older male patients
(13,15 %).
No other complications were observed in both groups.
No statistically significant differences (p = 0,9) were no-
ticed between the two groups in terms of post-operative
complications.
Table 1 Demographic pre-operative charateristic of the two groups












Young 69 42/27 57 ± 5,5 (range 42–64) 13 ± 4,25 44 ± 12,01 7 ± 5,59 4 ± 2,06 4 ± 1,54 1415 ± 567,28 14 (20 %)
Elderly 38 25/13 68 ± 2,34 (range 65–75) 13 ± 4,68 42 ± 12,34 10 ± 5,57 3 ± 1,50 4 ± 1,41 1360 ± 289,07 12 (32 %)
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Table 2 Previous literature on elderly and DBS surgical complications
Diagnosis Type of
procedure




















≥60ys 650 2,5 % N.r. N.r. 0,6 % N.r. 7.7 %
Entire cohort 1,183 2.2 % 0,4 % N.r. 0.6 % 0.4 % 6.8 %
Derost et al.
(2007)
PD STN-DBS <65ys 53 None 1.9 % 1.9 % None None 3.8 % 2 years Age ≥65ys is not
a surgical risk factor
≥65ys 34 None None None 2.9 % None 2.9 %














5446 1.9 % risk
for patients
>70ys
N.r. N.r. N.r. N.r. 3.5 % risk
for patients
>70ys












PD STN-DBS ≤55ys 29 N.r. N.r. 17.1 % N.r. N.r. 31.0 % 5 years Age ≥65ys is not a
surgical risk factor
56-64ys 52 N.r. N.r. 7.7 % N.r. N.r. 11.6 %
≥65ys 29 N.r. N.r. 13.8 % N.r. N.r.. 13.8 %










1757 OR 0.82 (95 % C.I
0.63 1.07) P = 0.14
OR 1.04 (95 % C.I
0.87–1.24) P = 0.69
N.r. OR 1.28 (95 % CI
0.99–1.64) P = 0,06
N.r OR 1.10 (95 % C.I
0.96–1.25) P = 0.17
90-days Age alone should




Present study PD STN-DBS <65ys 69 2,9 % 2,9 % None None None 5.8 % 90-days STN-DBS is a safe
surgical procedure
both in young and
elderly patients
≥65ys 38 7.9 % None None None None 7.9 %
Entire cohort 107 4.7 % 2.9 % None None None 6.5 %












In the western countries the term elderly is convention-
ally referred to as chronological age of 65 years and
older [19]. Great improvements in health and social care
have led to rapid growth of elderly population world-
wide. By 2030, a quarter of the European population will
be considered as elderly [14]. How this demographic
change will impact boundaries of everyday clinical prac-
tice represents a new, stimulating field of research
worldwide.
Elderly patients affected by PD are not traditionally con-
sidered optimal candidates for STN-DBS surgery [8, 9].
Despite evidence of equal motor fluctuation and dyskin-
esia reduction in elderly individuals, the mean age at
STN-DBS surgery for the treatment of PD is 58.6 years
[5, 15, 17]. One potential explanation could be that
neurologists and neurosurgeons often consider concomi-
tant disabling comorbidities of elderly subjects as STN-
DBS relative contraindications [3, 7, 8]. In addition, there
is evidence that elderly patients have higher rate of deteri-
oration in axial symptoms such as freezing of gait and
postural instability following surgery [15, 20, 21]. Finally,
in case of major surgical complication, elderly patients
may experience greater difficulty recovering and incresead
rate of secondary adverse events, such as pneumonia or
thromboembolism, because of their presumed decreased
physiologic reserve [22, 23]. These considerations have led
to exclude older patients from trials related to STN-DBS
[4, 5]. Therefore, data about their “surgical tolerability”
are limited to retrospective, nonrandomized studies
[15–18, 20, 22, 24].
Although few prior studies suggested that the rate of
surgical complications increases preferentially for older
patients undergoing DBS for the treatment of different
movement disorders, scant literature has directly ad-
dressed the relationship between patient age and surgical
adverse events in a population of patients affected by PD
undergoing STN-DBS [Table 2]. In a large multicenter
study by Voges et al., the authors concluded that age ≥
60 years and diagnosis of PD were risk factors associated
to major surgical complications and secondary adverse
events in a group of 1,183 patients treated for different
movement disorders [22]. Similar findings have been re-
ported by Rughani et al., who showed a negative prog-
nostic role for old age on surgical mortality and
complications in a study including a total of 5464
patients treated for PD, essential tremor and dystonia
with deep brain stimulation or ablation procedures [25].
Interestingly, in the two studies the primary diagnosis
of PD carried an increased likelihood of developing
post-operative complications, in particular intracranial
haemorrhage and pneumonia, if compared to other
movement disorders [22, 25]. Whether the increased
likelihood of intracranial haemorrhage may be direct
consequence of the different surgical target selected
(Pallidal Vs STN and thalamic DBS), the high prevalence
of frailty syndrome in subject affected by PD could be
one potential explanation for the high incidence of
pneumonia [9, 23, 24, 26, 27]. One limitation of these
studies was that they included different patient diagnosis
(PD, essential tremor, dystonia), modality treatments
(DBS, pallidotomy or thalamotomy), and targets (Stn,
Gpi and thalamus). The potential negative impact of in-
creased age on surgical complications in relation to the
PD population undergoing specifically STN-DBS was
not directly addressed. A recent large retrospective
cohort study (n = 1757) by DeLong et al. produced con-
tradictory findings on the argument, showing a similar
90-days complication risk for older parkinsonian pa-
tients and younger counterparts, suggesting that age
alone should not be a criteria for selecting patients can-
didates for DBS [18]. It is to notice, however, that in this
study the typology of neurostimulation is not reported
(subthalamic, thalamic or pallidal).
Unlike previous published literature, the present study
evaluates short-term surgical complication rate in rela-
tion to age in a specific group of patient undergoing
STN-DBS. The 90-days mortality was 0 %. Overall inci-
dence of permanent surgical adverse events was low
(6,54 %). These data agree with prior estimates for DBS-
related complications and confirm that STN-DBS, as a
matter of fact, is a minimally invasive surgical technique.
[3, 4] The cohort analysed in this study was charac-
terized by comparable disabilities, motor impairments
and risk factors at the baseline, differing only for age at
surgery. STN was the brain target in all cases. Older pa-
tients had no higher incidence of surgical complications
compared to the younger counterpart after STN-DBS.
This finding is in line with other previous studies [15, 17,
20]. Therefore, from a strictly surgical point of view, at
our institution chronological age of 65 years and older is
not be anymore considered as a relative contraindication
to STN-DBS surgery.
However, our data seem to suggest that surgical com-
plications, especially intracranial haemorrhage, may be
more severe in older patients. The only case in which an
urgent craniotomy was required for post-operative intra-
cranial haemorrhage, in fact, occurred in a 70-years sub-
ject with an unreported history of arterial hypertension.
Conversely, the 2 post-operative intracranial haemor-
rhages observed in the Young group were discovered
incidentally, being clinical asymptomatic. We also ob-
served a higher rate of post-operative confusion in
elderly subjects (13,15 % Vs 0 %). In all cases, the post-
operative confusion was transient (<24 h) and therefore
not considered as permanent surgical complication.
This study has some limitations due to its retrospective
and nonrandomized design. Procedure bias, as healthier
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aged individuals being preferentially selected for surgical
intervention, could have influenced our findings. More-
over, cognitive sequelae after STN-DBS has not been ana-
lysed because of the short-term period taken into account.
Conclusions
In conclusion, our study shows that STN-DBS is a safe
surgical procedure both in young and elderly patients.
Overall rate of short-term surgical complications did not
differ between patients aged < 65 years old and patients
aged ≥ 65 years old. From a strictly surgical point of view,
age alone should not considered as exclusion criteria to
determine STN-DBS surgical candidacy. In the next fu-
ture, multidisciplinary teams will be essential in order to
assess the “biological age” of patients candidates to STN-
DBS surgery and estimate their effective surgical risk.
Abbrevations
DBS: Deep brain stimulation; STN-DBS: Subthalamic nucleus deep brain
stimulation; PD: Parkinson’s disease; MRI: Magnetic resonance imaging;
UPDRS: Unified Parkinson’s disease rating scale; LED: Levodopa equivalent dose.
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